Video: The importance of publishing negative studies
Keith Flaherty is Director of Developmental Therapeutics at the Massachusetts Cancer Center. In his talk he addressed the benefits of publishing negative results. He focused his talk on therapies for cancer, in particular melanoma, since that’s the area he is most familiar with. (…) In closing, he emphasized that publishing negative data in preclinical and clinical studies would save time and money, and could open up new pathways of investigation.See the video here.